Enalapryl + lerkanidypina – unikatowe połączenie sprawdzonego doświadczenia z nowoczesnością? Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lip 11, 2018
Słowa kluczowe:
enalapryl, lerkanidypina, nadciśnienie tętnicze, terapia skojarzona
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze to istotny czynnik ryzyka chorób układu sercowo-naczyniowego. Jednym ze sposobów osiągnięcia zadowalającej kontroli ciśnienia tętniczego jest terapia skojarzona. W artykule omówiono połączenie inhibitora ACE i blokera kanału wapniowego na przykładzie enalaprylu i lerkanidypiny jako dwóch leków, które nie tylko są efektywne w działaniu hipotensyjnym, ale też mogą przynosić dodatkowe korzyści metaboliczne.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lewandowski , J., & Zygmunt , M. (2018). Enalapryl + lerkanidypina – unikatowe połączenie sprawdzonego doświadczenia z nowoczesnością?. Kardiologia W Praktyce, 12(2), 13-17. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1214
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Agrawal R., Marx A., Haller H.: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens. 2006; 24(1): 185-192.
2. Antza C., Stabouli S., Kotsis V.: Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence. Vasc. Health Risk Manag. 2016; 12: 443-451.
3. Barrios V., Escobar C., De La Figuera M. et al.: High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int. J. Clin. Pract. 2008; 62(5): 723-728.
4. Barrios V., Escobar C., Echarri R.: Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vasc. Health Risk Manag. 2008; 4(4): 847-853.
5. Barrios V., Navarro A., Esteras A. et al.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press. 2002; 11(2): 95-100.
6. Borghi C., Cicero A.F.: Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. Clin. Drug Investig. 2010; 30(12): 843-854.
7. Borghi C., Santi F.: Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer. Adherence 2012; 6: 449-455.
8. Cicero A.F., Gerocarni B., Rosticci M., Borghi C.: Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin. Exp. Hypertens. 2012; 34(2): 113-117.
9. Chatzikyrkou C., Haller H., Menne J.: Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension. Clinical Medicine. Therapeutics 2009; 1: CMT-S2315.
10. Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 1987; 316(23): 1429-1435.
11. De Ciuceis C., Salvetti M., Rossini C. et al.: Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J. Hypertens. 2014; 32(3): 565-574.
12. Grassi G.: Lercanidipine/enalapril combination in the management of obesity-related hypertension. Integr. Blood Press. Control. 2016; 9: 69-77.
13. Jamerson K.A., Nwose O., Jean-Louis L. et al.: Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am. J. Hypertens. 2004; 17(6): 495-501.
14. Januszewicz A., Prejbisz A.: Vademecum diagnostyki i leczenia nadciśnienia tętniczego. Poradnik dla lekarza praktyka. Medycyna Praktyczna, Kraków 2016.
15. Leonetti G., Magnani B., Pessina A.C. et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002; 15(11): 932-940.
16. Makani H., Bangalore S., Romero J. et al.: Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am. J. Med. 2011; 124(2): 128-135.
17. Mancia G., Coca A., Chazova I. et al.: Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J. Hypertens. 2014; 32(8): 1700-1707.
18. Mancia G., Omboni S., Chazova I. et al.; FELT Study Group: Effects of the lercanidipine–enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. J. Hypertens. 2016; 34(1): 139-148.
19. McInnes G.T.: Antihypertensive drugs in combination: additive or greater than additive? J. Hum. Hypertens. 2007; 21(12): 914-916.
20. Poncelet P., Ribstein J., Goullard L. et al.: Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann. Cardiol. Angeiol. (Paris) 2004; 53(3): 123-130.
21. Puig J.G., Calvo C., Luurila O. et al.: Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J. Hum. Hypertens. 2007; 21(12): 917-924.
22. Pruijm M.T., Maillard M.P., Burnier M.: Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc. Health Risk Manag. 2008; 4(6): 1159-1166.
23. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
24. Seravalle G., Brambilla G., Pizzalla D.P. et al.: Differential effects of enalapril–felodipine versus enalapril–lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J. Am. Soc. Hypertens. 2016; 10(3): 244-251.
25. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327(10): 685-691.
26. Tocci G., Palano F., Pagannone E. et al.: Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther. 2009; 7(2): 115-123.
27. Tykarski A., Narkiewicz K., Gaciong Z. et al. (red.): Zasady postępowania w nadciśnieniu tętniczym. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego 2015.
28. Verdecchia P., Reboldi G., Angeli F. et al.: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46(2): 386-392.
29. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 2009; 122(3): 290-300.
30. Williams B., Mancia G., Spiering W. et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018. http://doi.org/10.1093/eurheartj/ehy339.
31. Wojtyniak B., Goryński P. (red.): Sytuacja zdrowotna ludności Polski i jej uwarunkowania. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Warszawa 2016.
2. Antza C., Stabouli S., Kotsis V.: Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence. Vasc. Health Risk Manag. 2016; 12: 443-451.
3. Barrios V., Escobar C., De La Figuera M. et al.: High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int. J. Clin. Pract. 2008; 62(5): 723-728.
4. Barrios V., Escobar C., Echarri R.: Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vasc. Health Risk Manag. 2008; 4(4): 847-853.
5. Barrios V., Navarro A., Esteras A. et al.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press. 2002; 11(2): 95-100.
6. Borghi C., Cicero A.F.: Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. Clin. Drug Investig. 2010; 30(12): 843-854.
7. Borghi C., Santi F.: Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer. Adherence 2012; 6: 449-455.
8. Cicero A.F., Gerocarni B., Rosticci M., Borghi C.: Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin. Exp. Hypertens. 2012; 34(2): 113-117.
9. Chatzikyrkou C., Haller H., Menne J.: Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension. Clinical Medicine. Therapeutics 2009; 1: CMT-S2315.
10. Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 1987; 316(23): 1429-1435.
11. De Ciuceis C., Salvetti M., Rossini C. et al.: Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J. Hypertens. 2014; 32(3): 565-574.
12. Grassi G.: Lercanidipine/enalapril combination in the management of obesity-related hypertension. Integr. Blood Press. Control. 2016; 9: 69-77.
13. Jamerson K.A., Nwose O., Jean-Louis L. et al.: Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am. J. Hypertens. 2004; 17(6): 495-501.
14. Januszewicz A., Prejbisz A.: Vademecum diagnostyki i leczenia nadciśnienia tętniczego. Poradnik dla lekarza praktyka. Medycyna Praktyczna, Kraków 2016.
15. Leonetti G., Magnani B., Pessina A.C. et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002; 15(11): 932-940.
16. Makani H., Bangalore S., Romero J. et al.: Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am. J. Med. 2011; 124(2): 128-135.
17. Mancia G., Coca A., Chazova I. et al.: Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J. Hypertens. 2014; 32(8): 1700-1707.
18. Mancia G., Omboni S., Chazova I. et al.; FELT Study Group: Effects of the lercanidipine–enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. J. Hypertens. 2016; 34(1): 139-148.
19. McInnes G.T.: Antihypertensive drugs in combination: additive or greater than additive? J. Hum. Hypertens. 2007; 21(12): 914-916.
20. Poncelet P., Ribstein J., Goullard L. et al.: Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann. Cardiol. Angeiol. (Paris) 2004; 53(3): 123-130.
21. Puig J.G., Calvo C., Luurila O. et al.: Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J. Hum. Hypertens. 2007; 21(12): 917-924.
22. Pruijm M.T., Maillard M.P., Burnier M.: Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc. Health Risk Manag. 2008; 4(6): 1159-1166.
23. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
24. Seravalle G., Brambilla G., Pizzalla D.P. et al.: Differential effects of enalapril–felodipine versus enalapril–lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J. Am. Soc. Hypertens. 2016; 10(3): 244-251.
25. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327(10): 685-691.
26. Tocci G., Palano F., Pagannone E. et al.: Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther. 2009; 7(2): 115-123.
27. Tykarski A., Narkiewicz K., Gaciong Z. et al. (red.): Zasady postępowania w nadciśnieniu tętniczym. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego 2015.
28. Verdecchia P., Reboldi G., Angeli F. et al.: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46(2): 386-392.
29. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 2009; 122(3): 290-300.
30. Williams B., Mancia G., Spiering W. et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018. http://doi.org/10.1093/eurheartj/ehy339.
31. Wojtyniak B., Goryński P. (red.): Sytuacja zdrowotna ludności Polski i jej uwarunkowania. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Warszawa 2016.